Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.
Chatterjee M, Turner DC, Felip E, Lena H, Cappuzzo F, Horn L, Garon EB, Hui R, Arkenau HT, Gubens MA, Hellmann MD, Dong D, Li C, Mayawala K, Freshwater T, Ahamadi M, Stone J, Lubiniecki GM, Zhang J, Im E, De Alwis DP, Kondic AG, Fløtten Ø. Chatterjee M, et al. Among authors: ahamadi m. Ann Oncol. 2016 Jul;27(7):1291-8. doi: 10.1093/annonc/mdw174. Epub 2016 Apr 26. Ann Oncol. 2016. PMID: 27117531 Free PMC article. Clinical Trial.
Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma.
Chatterjee MS, Elassaiss-Schaap J, Lindauer A, Turner DC, Sostelly A, Freshwater T, Mayawala K, Ahamadi M, Stone JA, de Greef R, Kondic AG, de Alwis DP. Chatterjee MS, et al. Among authors: ahamadi m. CPT Pharmacometrics Syst Pharmacol. 2017 Jan;6(1):29-39. doi: 10.1002/psp4.12140. Epub 2016 Nov 29. CPT Pharmacometrics Syst Pharmacol. 2017. PMID: 27896938 Free PMC article.
Evaluation of dosing strategy for pembrolizumab for oncology indications.
Freshwater T, Kondic A, Ahamadi M, Li CH, de Greef R, de Alwis D, Stone JA. Freshwater T, et al. Among authors: ahamadi m. J Immunother Cancer. 2017 May 16;5:43. doi: 10.1186/s40425-017-0242-5. eCollection 2017. J Immunother Cancer. 2017. PMID: 28515943 Free PMC article.
Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response.
Li H, Yu J, Liu C, Liu J, Subramaniam S, Zhao H, Blumenthal GM, Turner DC, Li C, Ahamadi M, de Greef R, Chatterjee M, Kondic AG, Stone JA, Booth BP, Keegan P, Rahman A, Wang Y. Li H, et al. Among authors: ahamadi m. J Pharmacokinet Pharmacodyn. 2017 Oct;44(5):403-414. doi: 10.1007/s10928-017-9528-y. Epub 2017 Jun 1. J Pharmacokinet Pharmacodyn. 2017. PMID: 28573468
Development of a Disease Progression Model for Leucine-Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial Designs.
Ahamadi M, Conrado DJ, Macha S, Sinha V, Stone J, Burton J, Nicholas T, Gallagher J, Dexter D, Bani M, Boroojerdi B, Smit H, Weidemann J, Chen C, Yang M, Maciuca R, Lawson R, Burn D, Marek K, Venuto C, Stafford B, Akalu M, Stephenson D, Romero K; Critical Path for Parkinson's (CPP) Consortium. Ahamadi M, et al. Clin Pharmacol Ther. 2020 Mar;107(3):553-562. doi: 10.1002/cpt.1634. Epub 2019 Dec 5. Clin Pharmacol Ther. 2020. PMID: 31544231 Free PMC article.
Covariate modeling in pharmacometrics: General points for consideration.
Sanghavi K, Ribbing J, Rogers JA, Ahmed MA, Karlsson MO, Holford N, Chasseloup E, Ahamadi M, Kowalski KG, Cole S, Kerwash E, Wade JR, Liu C, Wang Y, Trame MN, Zhu H, Wilkins JJ; ISoP Standards & Best Practices Committee. Sanghavi K, et al. Among authors: ahamadi m. CPT Pharmacometrics Syst Pharmacol. 2024 May;13(5):710-728. doi: 10.1002/psp4.13115. Epub 2024 Apr 2. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 38566433 Free PMC article. Review.
24 results